tag:blogger.com,1999:blog-17606886985837772962024-02-19T04:58:11.909-05:00StepUp-SpeakOut.OrgHello and welcome to the <a href="http://www.stepup-speakout.org/">StepUp-SpeakOut.Org</a> Blog Site.
We will be using this blog for fast updates on news and information in the field of Secondary Lymphedema as a result of Breast Cancer.
We will be posting articles and information on new research and information, garments, etc., and invite your comments.Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.comBlogger108125tag:blogger.com,1999:blog-1760688698583777296.post-67032317348764247882016-04-06T14:51:00.000-04:002016-04-06T14:51:22.002-04:00<div class="post-headline" style="-webkit-text-size-adjust: auto; background-color: white; font-family: verdana, arial, sans-serif; font-size: 13px;">
<h1 style="font-family: Georgia, Palatino, 'Palatino Linotype', Times, 'Times New Roman', serif; font-size: 1.9em; font-weight: normal; line-height: 1.3; margin: 0px; padding: 0px;">
Debunking Lymphedema Risk Reduction Behaviors: Not So Fast</h1>
</div>
<div class="post-byline" style="-webkit-text-size-adjust: auto; background-color: white; color: #999999; font-family: verdana, arial, sans-serif; font-size: 11px; letter-spacing: 1px; margin: 5px 0px 10px; text-transform: uppercase;">
BY JOACHIM ZUTHER, ON APRIL 6TH, 2016</div>
<div class="post-bodycopy clearfix" style="-webkit-text-size-adjust: auto; background-color: white; font-family: verdana, arial, sans-serif; font-size: 13px; min-width: 0px;">
<iframe allowtransparency="true" class="fbLikeContainer" frameborder="0" id="fbLikeIframe" name="fbLikeIframe" scrolling="no" src="http://www.facebook.com/plugins/like.php?href=http%3A%2F%2Fwww.lymphedemablog.com%2F2016%2F04%2F06%2Fdebunking-lymphedema-risk-reduction-behaviors-not-so-fast%2F&layout=standard&show_faces=true&width=300&height=25&action=like&font=arial&colorscheme=light" style="border-style: none; display: inline; height: 25px; overflow: hidden; width: 300px;"></iframe><div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
<br /></div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
I would like to thank Dr. Judith Nudelman for writing this article on the importance of practicing appropriate <a href="http://www.lymphedemablog.com/2010/10/22/lymphedema-risk-reduction-venipuncture-and-blood-pressure/" style="color: #365da0; text-decoration: none;">risk reduction</a> for individuals affected by, or at risk of developing lymphedema.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
<img alt="judyheadshot" class="alignleft wp-image-2345" height="157" sizes="(max-width: 158px) 100vw, 158px" src="http://www.lymphedemablog.com/wp-content/uploads/2016/04/judyheadshot-300x298.jpg" srcset="http://www.lymphedemablog.com/wp-content/uploads/2016/04/judyheadshot-300x298.jpg 300x, http://www.lymphedemablog.com/wp-content/uploads/2016/04/judyheadshot-400x397.jpg 400x, http://www.lymphedemablog.com/wp-content/uploads/2016/04/judyheadshot.jpg 416x" style="background-color: #f3f3f3; border-bottom-left-radius: 3px; border-bottom-right-radius: 3px; border-top-left-radius: 3px; border-top-right-radius: 3px; border: 1px solid rgb(221, 221, 221); float: left; margin: 10px 10px 5px 0px; padding: 5px;" width="158" />Dr. Nudelman is an Associate Professor of Family Medicine, Clinical at Alpert Medical School, Brown University. She is also a Certified Lymphedema Therapist (CLT), and practices family medicine while also teaching at the medical school and serving on the board of licensure. She is a co-founder of stepupspeakout (www.stepup-speakout.org).</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
<br /></div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
This week I opened up a New England Journal of Medicine Journal Watch update and read: “Study Debunks Conventional Guidance in Lymphedema Prevention.”</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
This is a newsletter from a prestigious medical journal, reporting on a study from a Harvard affiliated hospital. It came from a very trustworthy source, could this practice changing information be trusted?</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
Well, I got the article and the editorial and I read every line, and found that the actual article didn’t prove that traumatizing an at risk arm with medical interventions was safe, and the editorial, unfortunately took a modest study and trumpeted that only two things cause lymphedema—obesity and infection—and taking blood pressures in the at risk arm should be the new normal. And then, the New England Journal took the editorial’s headline and dispersed it.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
So, if you don’t take the time to get the article, or don’t have access to it, you could be under the belief that new studies show that traumatizing an at risk arm is completely safe. But that would be wrong.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
On March 1, 2016 an article was published in the Journal of Clinical Oncology (1), from a group at Mass General who had followed over 600 women, taking perometry arm measurements at least 3 times, and they asked them if they’d had blood draws, injections, IV’s or blood pressure measurements in their at risk arm. Any woman who had flown on a plane and used compression was excluded from the study.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
The Mass General study measured women with perometry, a laser measurement that is very good at measuring the volume of an arm from the wrist up. They defined a significant change as a 10% increase. They were careful NOT to say that women developed lymphedema, as there is no universal definition of lymphedema, but rather limited their findings to “increased swelling.”</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
Most women avoided medical trauma to their arms: only 2.1% had an injection and 8.5% had a blood draw.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
The study concluded: “Although we cannot affirmatively state that risk-reduction practices have no effect on arm swelling, we hope to generate evidence that brings reasonable doubt to burdensome guidelines and encourage further investigation into non-precautionary behaviors and the risk of lymphedema. “</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
So, they didn’t find that in the small numbers of their patients who recalled having medical procedures in their arms or flew without compression that they had a large increase in swelling of the part of their arms they could measure. But they couldn’t definitively say it was safe.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
The limitations of the study were that only a small percentage of the women recalled that they were exposed to risk, that it was self-reported, and that the perometer can’t measure swelling in hands, breasts, trunks—the entire quadrant that is at risk in breast cancer.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
Also, volume measurement, used alone isn’t that sensitive for diagnosing lymphedema. Another study found that in 50 women, 5% measured a 10% increase but when they were clinically evaluated, an additional 31% had arm lymphedema and 8% had hand lymphedema. (4)</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
In the same Journal of Clinical Oncology, the article was reviewed (2), and these reviewers came to the conclusion that only obesity and infection are risk factors for lymphedema—ignoring all of the other risk factors such as radiation, number of nodes removed, genetic predisposition, chemotherapy and aging and stated: “As for other preventative behaviors, patients should be informed that there are not enough data to justify recommending strict adherence to avoiding skin punctures, blood pressure measurements, or use of compressive garments for <a href="http://www.lymphedemablog.com/2015/04/17/lymphedema-and-airline-travel/" style="color: #365da0; text-decoration: none;">air travel</a>.”</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
This editorial looked at an older article for determining if women should wear compression for air travel (3). It’s not a great article. And even its author, who felt women shouldn’t wear garments on flights less than 4.5 hours, concluded: “this is not to say that there is no risk, or no women at risk, or that swelling never occurs.”</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
So, where does this leave the person at risk for lymphedema and their healthcare providers?</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
If their providers just read the one line synopsis, they might conclude that reputable journals have proved that no risk reduction behaviors are needed for lymphedema.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
And that puts women in a very difficult place, as they may ask not to have blood pressure measurements—especially the high pressure automatic cuffs—or IV’s, or blood draws in their at risk arm and be met with resistance.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
I asked Jane Armer, a noted researcher and head of the American Lymphedema Framework Project to review these articles, and she felt that as a clinician and researcher, they don’t change her recommendations. Avoid unnecessary trauma to an at risk arm.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
The most controversial issue is the use of compression garments while flying in a person who has not developed lymphedema. The consensus is that at risk women should be carefully evaluated and discuss this with a knowledgeable physician, and if they chose to wear compression on a flight, to have it well fitted and to compress the hand as well as the arm.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
Lymphedema is incurable. Why risk it? Even a low risk procedure will be 100% if it triggers lymphedema.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
The movement to debunk lymphedema risk reduction behaviors comes from a desire to unburden women. Yet having lymphedema is a tremendous burden.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
Risk reduction behaviors have not been debunked. But your healthcare provider might not have read the entire article, so you may have to advocate for yourself, or inform them.</div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px; text-align: center;">
<a href="http://www.lymphedemablog.com/wp-content/uploads/2016/04/JNudelmandebunk.pdf" rel="" style="color: #365da0; text-decoration: none;">Click Here for a PDF Version of this Article</a></div>
<div style="margin-bottom: 1em; margin-top: 1em; padding: 0px;">
<br /></div>
<ol style="margin-bottom: 10px; margin-top: 10px; padding-bottom: 0px; padding-top: 0px;">
<li>Ferguson CM, Swaroop MN, Horick N, et al: Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol March 1, 2016 34:691-698</li>
<li>Ahn S, Port ER: Lymphedema Precautions: Time to Abandon Old Practices? J Clin Oncol March 1, 2016 34: 655-658</li>
<li>Graham PH: Compression prophylaxis may increase the potential for flight-associated lymphoedema after breast cancer treatment. Breast 11: 66-71, 2002</li>
<li>Jeffs E, Purushotham A, Springerplus, 2016 Jan ;5:21, The prevelance of lymphoedema in women who attended an information and exercise class to reduce the risk of breast cancer-related upper limb lymphoedema</li>
</ol>
<iframe allowtransparency="true" class="fbLikeContainer" frameborder="0" id="fbLikeIframe" name="fbLikeIframe" scrolling="no" src="http://www.facebook.com/plugins/like.php?href=http%3A%2F%2Fwww.lymphedemablog.com%2F2016%2F04%2F06%2Fdebunking-lymphedema-risk-reduction-behaviors-not-so-fast%2F&layout=standard&show_faces=true&width=300&height=25&action=like&font=arial&colorscheme=light" style="border-style: none; display: inline; height: 25px; overflow: hidden; width: 300px;"></iframe></div>
<div>
<br /></div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-67207675914271687472016-01-14T12:18:00.002-05:002016-01-14T12:18:46.694-05:00New Lymphedema Telephone Support Group<div style="font-family: 'Times New Roman'; font-size: 10px; min-height: 11px;">
<br /></div>
<div style="font-family: 'Times New Roman'; font-size: 11px; margin-top: 0.6px; min-height: 12px;">
<br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10px; margin-left: 6px; min-height: 11px;">
<br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10px; min-height: 11px;">
<br /></div>
<div style="color: #e4ae4d; font-family: 'Times New Roman'; font-size: 24px; text-align: right;">
<b>NEW</b></div>
<div style="color: #e4ae4d; font-family: 'Times New Roman'; font-size: 24px; margin-top: 1.2px; text-align: right;">
<span style="letter-spacing: -1.6px;"><b>L</b></span><b>ymphedema</b><span style="letter-spacing: -1.2px;"><b> </b></span><span style="letter-spacing: -2.8px;"><b>T</b></span><b>elephone</b></div>
<div style="color: #e4ae4d; font-family: 'Times New Roman'; font-size: 24px; margin-top: 1.2px; text-align: right;">
<span style="letter-spacing: 0.1px;"><b>Support</b></span><span style="letter-spacing: -2.6px;"><b> </b></span><span style="letter-spacing: -0.1px;"><b>Group</b></span></div>
<div style="font-family: 'Times New Roman'; font-size: 10px; min-height: 11px;">
<b></b><br /></div>
<div style="color: #2f2a2b; font-family: 'Times New Roman'; font-size: 14px; margin-left: 184.5px; margin-top: 9.3px; text-align: right; text-indent: 80.2px;">
<span style="letter-spacing: -0.5px;">T</span><span style="letter-spacing: -0.3px;">alk</span><span style="letter-spacing: 1.8px;"> </span>with<span style="letter-spacing: 1.8px;"> </span>other<span style="letter-spacing: 1.8px;"> </span><span style="letter-spacing: -0.1px;">women</span><span style="letter-spacing: 1.8px;"> </span>with<span style="letter-spacing: 1.8px;"> </span>lymphedema.<span style="letter-spacing: 1.2px;"> </span>Call<span style="letter-spacing: 0.5px;"> </span>the<span style="letter-spacing: 0.5px;"> </span>SHARE<span style="letter-spacing: 0.5px;"> </span><span style="letter-spacing: -0.1px;">Breast</span><span style="letter-spacing: 0.5px;"> </span>Cancer<span style="letter-spacing: 0.5px;"> </span>Helpline<span style="letter-spacing: 0.6px;"> </span><span style="letter-spacing: -0.3px;">t</span><span style="letter-spacing: -0.2px;">o</span><span style="letter-spacing: 0.5px;"> </span><span style="letter-spacing: -0.2px;">r</span><span style="letter-spacing: -0.1px;">egister</span><span style="letter-spacing: 0.5px;"> </span>and<span style="letter-spacing: 1.4px;"> </span><span style="letter-spacing: -0.2px;">r</span><span style="letter-spacing: -0.1px;">eceive</span><span style="letter-spacing: 3.0px;"> </span>instructions<span style="letter-spacing: 3.0px;"> </span>on<span style="letter-spacing: 3.0px;"> </span><span style="letter-spacing: -0.1px;">how</span><span style="letter-spacing: 3.1px;"> </span><span style="letter-spacing: -0.3px;">t</span><span style="letter-spacing: -0.2px;">o</span><span style="letter-spacing: 3.0px;"> </span><span style="letter-spacing: -0.1px;">participate:</span></div>
<div style="color: #2f2a2b; font-family: 'Times New Roman'; font-size: 14px; text-align: right;">
(212)<span style="letter-spacing: 0.1px;"> </span>382-2111<span style="letter-spacing: 0.1px;"> </span>or<span style="letter-spacing: 0.1px;"> </span>(844)<span style="letter-spacing: 0.1px;"> </span>275-7427<span style="letter-spacing: 0.1px;"> </span><span style="letter-spacing: -0.1px;">(toll</span><span style="letter-spacing: 0.1px;"> </span><span style="letter-spacing: -0.2px;">fr</span><span style="letter-spacing: -0.1px;">ee)</span></div>
<br />
<div style="color: #2f2a2b; font-family: 'Times New Roman'; font-size: 14px; margin-top: 0.7px; text-align: right;">
<span style="letter-spacing: -0.1px;"><i>Thursdays,</i></span><span style="letter-spacing: -1.8px;"><i> </i></span><i>8:15-9:15 pm </i><span style="letter-spacing: -0.4px;"><i>ET;</i></span><span style="letter-spacing: 3.1px;"><i> </i></span><span style="letter-spacing: -0.1px;"><i>Jan </i></span><i>14 Mar 10</i></div>
<div>
<i><br /></i></div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-46128566094596380832016-01-14T12:00:00.000-05:002016-01-14T12:00:09.627-05:00NYU College of Nursing study on obesity and BCRL<a href="http://www.nyu.edu/about/news-publications/news/2015/12/15/nyu-college-of-nursing-study-examines-obesity-in-relation-to-breast-cancer-related-lymphedema.html" target="_blank">NYU College of Nursing study examines obesity and breast cancer related lymphedema</a><br />
<br />
<div class="date" style="border: 0px none; color: #818790; font-family: verdana, arial, helvetica, sans-serif; font-size: 11px; font-weight: bold; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
December 15, 2015 <br style="border: 0px none; list-style-type: none; padding: 0px;" /><span class="volume" style="border: 0px none; font-weight: normal; list-style-type: none; padding: 0px;">N-157 2015-16</span></div>
<div class="parsys main" style="border: 0px none; font-family: verdana, arial, helvetica, sans-serif; font-size: 11px; list-style-type: none; padding: 0px;">
</div>
<div class="body text parbase nyuRichText" style="border: 0px none; font-family: verdana, arial, helvetica, sans-serif; font-size: 11px; list-style-type: none; padding: 0px;">
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
<strong style="border: 0px none; list-style-type: none; padding: 0px;"><em style="border: 0px none; list-style-type: none; padding: 0px;">Lymphedema expert Dr. Mei R. Fu looks to mitigate risk of post-surgery comorbidities through patient education and awareness counseling</em></strong></div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
Each year, about 1.38 million women worldwide are diagnosed with breast cancer. Advances in treatment have facilitated a 90% five-year survival rate among those treated. Given the increased rate and length of survival following breast cancer, more and more survivors are facing life-time risk of developing late effects of cancer treatment that negatively impact long-term survival. In particular, Breast cancer-related lymphedema is one of the most distressing and feared late effects.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
Lymphedema, characterized by the abnormal swelling of one or more limbs, is most often the result of an obstruction or disruption of the lymphatic system over the course of the cancer treatment. Lymphedema usually manifests after a latent period of one to five, or even twenty years, after treatment. Consequently, lymphedema remains a major health problem affecting many breast cancer survivors and exerting a tremendous negative impact on survivors’ quality of life. Although at present, no surgery or medication can cure lymphedema, this condition can be managed with early and appropriate treatment.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
“Obesity is an established risk factor not only for breast-cancer related lymphedema but also for breast cancer occurrence, recurrence, and fatality,” says Mei R. Fu, PhD, RN, ACNS-BC, FAAN, associate professor of Chronic Disease Management at the New York University College of Nursing (NYUCN). “Accordingly, we believe obesity is a significant, but modifiable risk factor for lymphedema.”</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
However, Dr. Fu notes existing research has produced conflicting findings. For example, some studies suggest that obesity is a risk factor when defined as having a body mass index (BMI) of 30 kg/m2 or more, while others posit the risk is posed with as low of a BMI as 25 kg/m2.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
Such discrepancies are in part due to study limitations, such as retrospective assessments, small sample sizes, and self-reports. To bridge the gap, a team of NYUCN researchers, led by Dr. Fu conducted a stu<a href="http://www.mdpi.com/2075-4426/5/3/326" style="border: 0px none; color: #d11255; list-style-type: none; outline: none; padding: 0px; text-decoration: none;" target="_blank">dy,” Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study</a>,” designed to prospectively investigate patterns of obesity as it relates to lymphedema. The team’s findings were published in the <em style="border: 0px none; list-style-type: none; padding: 0px;">Journal of Personalized Medicine</em>.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
“We determined the best way to quantify the relationship between obesity and lymphedema, was to first examine obesity as it relates to lymph fluid level,” said Dr. Fu. “Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study,” followed 140 women through their first year of cancer treatment, measuring their lymph fluid levels—known as L-Dex values—and weight before their surgeries, four to eight weeks and a year post-op.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
General instructions were given to participants on maintaining pre-surgery weight. Among the 140 participants, 136 completed the study. More than 60% of the participants were obese (30.8%) or overweight (32.4%), while only two participants were underweight and about 35% measured at normal weight. This pattern of obesity and overweight was consistent at four to eight weeks and twelve months post-surgery. At twelve months post-surgery, the majority of the women (72.1%) maintained pre-surgery weight and 15.4% had lost more than 5% of their weight; 12.5% of the women experienced more than a 5% increase in weight. L-Dex values consistent with lymphedema were particularly prevalent in patients with a BMI greater than 30 kg/m2, this trend was observed throughout the study.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
Obesity and overweight remain among women at the time of cancer diagnosis and the patterns of obesity and overweight continue during the first year of treatment.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
“General instructions on having nutrition-balanced and portion-appropriate diet and physical activities daily or weekly can be effective to maintain pre-surgery weight,” says Dr. Fu. “Such general instructions may create less burden and stress to women when facing the diagnosis and treatment of breast cancer.”</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
<strong style="border: 0px none; list-style-type: none; padding: 0px;">Researcher Affiliations: </strong>Mei R. Fu 1, Deborah Axelrod 2,3, Amber A. Guth 2,3, Jason Fletcher 1, Jeanna M. Qiu 1, Joan Scagliola 3, Robin Kleinman 3, Caitlin E. Ryan 1, Nicholas Chan 1 and Judith Haber 1.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
1. College of Nursing, New York University, 433 First Avenue, New York, NY 10010, USA</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
2. Department of Surgery, School of Medicine, New York University, 160 East 34 Street, New York, NY 10016, USA</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
3. NYU Laura and Isaac Perlmutter Cancer Center, 160 East 34 Street, New York, NY 10016, USA</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
<strong style="border: 0px none; list-style-type: none; padding: 0px;">Acknowledgements:</strong> the National Institute of Health (NINR Project # 1R21NR012288-01A supported this study and NIMHD Project # P60 MD000538-03). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH and other funders. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</div>
<div style="border: 0px none; line-height: 16px; list-style-type: none; margin-bottom: 12px; margin-left: 15px; margin-right: 15px; padding: 0px;">
<br /></div>
</div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-8836960889609912002015-10-22T12:47:00.000-04:002015-10-22T12:47:25.402-04:00 Symptom report in detecting breast cancer-related lymphedema<br />
<span style="-webkit-text-size-adjust: 100%; background-color: white; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 19px; font-weight: bold; line-height: 25.78125px;">Symptom report in detecting breast cancer-related lymphedema</span><br />
<span style="-webkit-text-size-adjust: 100%; background-color: white; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 19px; font-weight: bold; line-height: 25.78125px;"><br /></span>
<span style="-webkit-text-size-adjust: 100%; background-color: white; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 19px; font-weight: bold; line-height: 25.78125px;"><a href="https://www.dovepress.com/symptom-report-in-detecting-breast-cancer-related-lymphedema-peer-reviewed-article-BCTT" target="_blank">https://www.dovepress.com/symptom-report-in-detecting-breast-cancer-related-lymphedema-peer-reviewed-article-BCTT</a></span>
<span style="-webkit-text-size-adjust: 100%; background-color: white; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 19px; font-weight: bold; line-height: 25.78125px;"><br /></span>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-7325006719846217542015-10-20T22:56:00.000-04:002015-10-20T22:56:24.011-04:00Join us at 20th Annual Ellen P. Hermanson symposium October 26<br />
<blockquote style="font-family: Calibri;" type="cite">
<b><a href="https://www.dropbox.com/s/lwcfqlj1oxpbyoe/hermanson%20symposium-4.pdf?dl=0" target="_blank">Join us at 20th Annual Ellen P. Hermanson symposium October 26</a></b></blockquote>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-66666394310316500162015-10-06T14:50:00.001-04:002015-10-06T14:50:53.945-04:00Clarification to previous post. Having Lymphedema is not required to participate in this studyDr. Mei Fu of NYU is recruiting participants for a study on Lymphedema and pain after breast cancer surgery. You do not need to have Lymphedema to participate in this study.<br />
<br />
<blockquote style="-webkit-text-size-adjust: auto; font-family: UICTFontTextStyleBody; font-size: 17px;" type="cite">
<div dir="ltr">
<div class="gmail_default" style="font-family: verdana, sans-serif;">
<span style="font-size: 12.8px;">I am writing to ask for your help! We are still needing 90 patients for our study on pain after breast cancer treatment. As long as patients have pain, soreness, aching, tenderness in their affected body side or limb 3 months after surgery, they are eligible for the study. The study will have two different upper body exercises and the patients will be in the study for 3 months. They will receive $100 after the study.</span></div>
</div>
</blockquote>
<br />
<a href="https://www.dropbox.com/s/oyxknltdz99ldil/Study%20Flyer_Approved%209%2010%202015.pdf?dl=0" target="_blank">Information on study.</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-29308208729156091752015-10-06T13:56:00.000-04:002015-10-06T14:37:02.905-04:00Please participate in Lymphedema and Pain StudyDr. Mei Fu of NYU is recruiting participants for a study on Lymphedema and pain after breast cancer surgery. You do not need to have Lymphedema to participate in this study.<br />
<br />
<blockquote style="-webkit-text-size-adjust: auto; font-family: UICTFontTextStyleBody; font-size: 17px;" type="cite">
<div dir="ltr">
<div class="gmail_default" style="font-family: verdana, sans-serif;">
<span style="font-size: 12.8px;">I am writing to ask for your help! We are still needing 90 patients for our study on pain after breast cancer treatment. As long as patients have pain, soreness, aching, tenderness in their affected body side or limb 3 months after surgery, they are eligible for the study. The study will have two different upper body exercises and the patients will be in the study for 3 months. They will receive $100 after the study.</span></div>
</div>
</blockquote>
<br />
<a href="https://www.dropbox.com/s/oyxknltdz99ldil/Study%20Flyer_Approved%209%2010%202015.pdf?dl=0" target="_blank">Information on study.</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-74653393656099832352015-10-06T13:47:00.000-04:002015-10-06T13:47:57.334-04:00Learn about and support the Lymphedema Treatment Act<a href="https://youtu.be/GQZuvWs4-Pc">Learn about and support the Lymphedema Treatment Act</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-72610654296473959282015-03-05T16:35:00.001-05:002015-03-05T16:35:42.231-05:00YouTube Presentation How to Find a Qualified Lymphedema Therapist<a href="http://youtu.be/EkYMZFLWzlI">YouTube of Dr. Judith Nudelman's presentation on How to Find a Qualified Lymphedema Therapist</a> made in conjunction with Lymphatic Education and Research Network<br />
<br />
<h3 class="js-event_details_component detail" style="border: 0px; color: #666666; font-family: Helvetica, Arial, 'Helvetica Neue', sans-serif; font-size: 12px; line-height: 20px; margin: 10px 0px 0px; padding: 0px; word-break: break-word; word-wrap: break-word;">
About</h3>
<div class="js-event_details_component detail" style="border: 0px; color: #777777; font-family: Helvetica, Arial, 'Helvetica Neue', sans-serif; font-size: 12px; line-height: 18px; padding: 0px 0px 5px; word-break: break-word; word-wrap: break-word;">
Dr. Judith Nudelman is a Board Certified family medicine physician who combines clinical work with medical student education, and is a clinical associate professor of family medicine at Brown University. She received her MD from University of Pittsburgh and her BA from University of Michigan, and did her residency in Family Medicine at Brown University. Her interest in lymphedema stems from personal experience and her subsequent discovery of widespread lack of knowledge of both the condition of lymphedema and its treatment, and her inability to discover a physician who was capable of or interested in managing the condition. Her goal is to provide education and information about lymphedema and to work to encourage physicians to manage the condition in their patients. She is a CLT (certified lymphedema therapist), and served on the board of directors of the Lymphology Association of America. She has written textbook chapters and articles on lymphedema, and lectures on the subject.</div>
<br />
<br />Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-58301273768042035492015-03-05T15:42:00.001-05:002015-03-05T15:42:47.944-05:00Podcast on Lymphedema by Dr. Judith NudelmanStepUp SpeakOut shared a link<br />
<br />
Expert & Patient Perspective on Lymphedema<br />
<br />
In this podcast, Certified Lymphedema Therapist and patient Judith Nudelman MD, CLT, shares what lymphedema is and how to manage it.<br />
CANCER.NET<br />
<br />
<a href="http://www.cancer.net/blog/2015-03/expert-patient-perspective-lymphedema">http://www.cancer.net/blog/2015-03/expert-patient-perspective-lymphedema</a><br />
<br />
<br />
Tomorrow marks Lymphedema Awareness Day, which provides the opportunity to share personal stories and learn more about new strategies to manage this condition. Lymphedema is the swelling and inflammation caused by fluid buildup from damage to the lymph nodes. Although it often occurs in the arms and legs, it can happen anywhere in the body, after treatment from any type cancer.<br />
<br />
Dr. Judith Nudelman’s story is compelling. Not only is she a family physician and Certified Lymphedema Therapist, but she also has personal experience with this topic. She developed lymphedema after treatment for breast cancer.<br />
<br />
Speaking as both a patient and expert, she offers clinical advice and provides insight on coping strategies from personal experience, such as finding support in an online forum. Some people have said that there is no treatment for lymphedema. Dr. Nudelman clarifies that “nothing could be further from the truth.”<br />
<br />
<div>
<br /></div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-88763870636696258392014-09-17T15:56:00.001-04:002014-09-17T15:56:32.124-04:00Article written by Oncology Times about the NLN Conference and the Lymphedema Treatment Act Bill.<div class="separator" style="clear: both; text-align: center;">
<span style="background-color: white; color: #141823; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 19px; text-align: left;">Here's a great article written by<a href="http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=1136"> Oncology Times</a> about the NLN Conference and the Lymphedema Treatment Act Bill.</span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="background-color: white; color: #141823; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 19px; text-align: left;"><br /></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="color: #1a1a1a; font-family: "Trebuchet MS"; font-size: 16.0pt; mso-bidi-font-family: "Trebuchet MS";">Tuesday, September 09, 2014<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "Trebuchet MS"; font-size: 18.0pt; mso-bidi-font-family: "Trebuchet MS";">ONLINE FIRST: Lymphedema Conference
Stresses Need for Better Education, Medicare Coverage of Compression Supplies<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: Arial; font-size: 13.0pt; mso-no-proof: yes;"><!--[if gte vml 1]><v:shapetype
id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter"/>
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0"/>
<v:f eqn="sum @0 1 0"/>
<v:f eqn="sum 0 0 @1"/>
<v:f eqn="prod @2 1 2"/>
<v:f eqn="prod @3 21600 pixelWidth"/>
<v:f eqn="prod @3 21600 pixelHeight"/>
<v:f eqn="sum @0 0 1"/>
<v:f eqn="prod @6 1 2"/>
<v:f eqn="prod @7 21600 pixelWidth"/>
<v:f eqn="sum @8 21600 0"/>
<v:f eqn="prod @7 21600 pixelHeight"/>
<v:f eqn="sum @10 21600 0"/>
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
<o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
style='width:252pt;height:81pt;visibility:visible;mso-wrap-style:square'>
<v:imagedata src="file://localhost/Users/janedweck1/Library/Caches/TemporaryItems/msoclip/0/clip_image001.jpg"
o:title=""/>
</v:shape><![endif]--><!--[if !vml]--><!--[endif]--></span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://journals.lww.com/oncology-times/PublishingImages/Lymphedema%20Conference--2014.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://journals.lww.com/oncology-times/PublishingImages/Lymphedema%20Conference--2014.jpg" height="102" width="320" /></a></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">BY
PEGGY EASTMAN</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">WASHINGTON—After
years of languishing on the back burner, lymphedema is now being recognized as
an increasingly important health care issue, according to speakers here at the
11th National Lymphedema Network (NLN) International Conference.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Speakers
and conference participants emphasized the need for better professional and
patient education; high-quality medical treatment for all patients at risk for
or affected by lymphedema; insurance coverage of compression supplies; and
expansion of the number of lymphedema treatment centers and certified
lymphedema therapists (CLTs).<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Health
professionals are now increasingly aware of the importance of early detection
of lymphedema, risk reduction, and possibly prevention, said Kathleen Francis,
MD, Medical Director of Lymphedema Physician Services at St. Barnabas
Ambulatory Care Center in Livingston, NJ, who moderated a session on breast
cancer-related lymphedema detection and risk reduction.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Marga
F. Massey, MD, CLT, a surgeon, who is founder and Chief Participating
Investigator of the National Institute of Lymphology in Chicago, told <i>OT </i>that
she had taken time to complete a two-week course to become a certified
lymphedema therapist because she believes so strongly in the need for
high-quality lymphedema care: “Anybody involved with this patient population
should study lymphedema,” she said. “My vision is that every single nurse
should undergo CLT training.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">Lymphedema
Treatment Act (H.R.3877)</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Conference
participants urged Congress to pass the Lymphedema Treatment Act (H.R. 3877),
which is supported by the NLN, the American Cancer Society, the Oncology Nursing
Society, Susan G. Komen for the Cure, and LIVESTRONG, among others. This act
would change Medicare law to allow coverage of the physician-prescribed
lymphedema compression supplies many cancer patients use daily, including
gradient compression garments, bandages, and devices such as reduction kits.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Currently,
Medicare does not cover these mainstay treatment supplies; the lymphedema
community hopes that if Medicare approves coverage of compression supplies,
other insurers will follow suit. The Act was introduced in January by Rep.
David G. Reichert (R-WA).<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">The
aim is to support patients’ adherence to their maintenance phase of treatment
by covering compression supplies and to reduce total lymphedema health care
costs by decreasing the incidence of complications, co-morbidities, and
disabilities resulting from lymphedema.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">NLN
notes that many lymphedema patients cannot afford compression supplies, and
thus suffer from recurrent infections, worsening of their condition and
eventual disability. The Lymphedema Advocacy Group is leading the effort to
pass the Lymphedema Treatment Act, and conference participants visited Capitol
Hill to lobby for the Act’s passage.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">‘Protect
the Limb’ Protocol</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">At
the conference, Massey presented results of a study on her proactive Protect
the Limb protocol, which seeks to lower patients’ risk of developing breast
cancer-related lymphedema (BCRL). In this study at St. Charles Surgical
Hospital in New Orleans of 2,966 consecutive patients, the patients underwent a
protocol of education and participative decision-making about breast
cancer-related lymphedema overall as well as on the sites for future at-risk
interventions such as venipuncture, IV catheter placement, and blood pressure
monitoring prior to the day of surgery.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">The
patient education was given by a CLT and took two hours. “We hypothesized that
giving tools for patients to proactively participate in making decisions that
may alter their risk of developing BCRL would be a major contributor to patient
satisfaction with their hospital care,” she said. “In our practice we’ve used
lots of tools for patient education.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Patients
were given copies of NLN position papers for home study. At a second meeting,
an 89-item questionnaire was administered by the peri-operative nursing staff
to determine a numerical BCRL risk score for each limb. That score was
translated into a risk-associated color code for each limb; the patients and
anesthesiologist then selected which limb(s) were appropriate for at-risk
interventions before any additional testing or procedures were done.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">For
example, she said, red means “stop;” yellow means “caution” related to an
at-risk extremity; and green means “go” – that is, the limb is cleared for
procedures. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">“All
patients who went through the Protect the Limb protocol said that that the
ability to participate in proactively determining how to reduce their potential
risk of BCRL prior to surgery was a major contributor to their overall
satisfaction in their hospital care,” Massey said. She and her team concluded
that “system-wide educational programs can be developed to educate patients as
to risk-reduction practices for BCRL.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Asked
who on the breast cancer patient’s care team is responsible for patient
education on lymphedema, Massey said that job falls to everyone, but it should
be led by a certified lymphedema therapist: “I had to go and become a CLT so I
could educate myself,” she said. “Then I had to go and educate others in the
hospital. It was a relatively large task to get everybody on board.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">For
example, she said, anesthesiologists knew little about lymphedema. She added
that getting a buy-in from surgeons for a patient education protocol such as
Protect the Limb is “very hard, and takes effort.” Is it practical, though for
surgeons to take CLT training, as she did? “Why not?,” she answered. “It only
takes two weeks. No one has a fuller surgical schedule than I do.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">Prospective
Surveillance Model for Rehabilitation for Women with Breast Cancer</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">A
second noteworthy study at the conference presented the first report of
implementation of the Prospective Surveillance Model (PSM) for Rehabilitation
for Women with Breast Cancer, which is aimed at early detection of, and
intervention for, lymphedema.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">In
this feasibility study at Grady Memorial Hospital, a large inner-city facility
in Atlanta, 100 subjects with Stages 0-III breast cancer received education
related to lymphedema risk reduction, treatment side effects, and the
importance of both early therapeutic range-of-motion exercise and ongoing
exercise habits. Each patient had a patient navigator.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">The
lead author Jill Binkley, PT, MSc, CLT, Executive Director of TurningPoint
Breast Cancer Rehabilitation in Atlanta reported that about 35 percent of women
admitted to the two-year PSM study required further physical therapy
intervention, including lymphedema management. Early, mild lymphedema was
detected and treated in 18 percent of patients.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">PSM
education helped to maintain a low level of lymphedema in the majority of
patients, she said, adding that the protocol “serves to empower women to
self-manage and to know when to return to us for further treatment.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">Differences
in Lymphedema Based on One or Two Mastectomies?</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Another
study of 916 surveys from 229 women – conducted at Massachusetts General
Hospital – who had either a unilateral or bilateral mastectomy found no
difference in breast cancer-related lymphedema, based on an analysis of 355
mastectomies, between those who had one breast removed and those who had two
breasts removed.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">There
were also no significant differences in mean arm function score and quality of
life, said lead author Meyha N. Swaroop, an investigator in Massachusetts
General Hospital’s Department of Radiation Oncology. Kathleen Francis, MD,
commented as moderator, “Since all of us are seeing more and more bilateral
mastectomies, this kind of information is very important to have.”<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<b><span style="font-family: Arial; font-size: 13.0pt;">With/Without
Axillary Surgery</span></b><span style="font-family: Arial; font-size: 13.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: Arial; font-size: 13.0pt;">Finally,
another study from Massachusetts General Hospital of 348 breast cancer patients
over age 65 explored BCRL in those who underwent breast surgery with or without
axillary surgery. This study showed that in elderly patients, staging the
axilla with sentinel lymph node (SLN) biopsy compared with no axillary surgery
is associated with a similar risk of breast cancer-related lymphedema, as well
as similar postoperative complications and locoregional recurrence.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: 1.0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves>false</w:TrackMoves>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal" style="margin-left: 1.0in;">
<span style="font-family: Arial; font-size: 13.0pt;">Therefore, said lead author Chantal M. Ferguson, the
decision to proceed with SLN should be based not on age but “on how the
pathologic nodal information will influence decisions regarding adjuvant
treatment.”</span><o:p></o:p></div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-59838117307278850432014-09-17T14:57:00.000-04:002014-09-17T14:57:09.341-04:00Dr. Mei Fu to speak at SHARE Cancer Support September 29, 2014<span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">Dr. Mei Fu, author of the <a href="http://www.ascopost.com/ViewNews.aspx?nid=16256">Optimal Lymph Flow Program</a>, will be giving a talk:</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">Learn how to manage lymphedema</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">and how to prevent its onset. </span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">She will share tips about taking action to lower your</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">risk and to manage lymphedema.</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">Monday, September 29, 2014</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">6:00—7:30pm</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">SHARE Main Office</span><br style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;" /><span style="background-color: white; color: #37404e; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;">1501 Broadway (bet. 43rd & 44th St.),</span><span class="text_exposed_show" style="background-color: white; color: #37404e; display: inline; font-family: Helvetica, Arial, 'lucida grande', tahoma, verdana, arial, sans-serif; font-size: 14px; line-height: 20px;"><br />Suite 704A, 7th Floor<br />New York, New York<br /><br />To register or for more information:<br /> (212) 719-2943<br /><a href="mailto:rsvp@sharecancersupport.org">rsvp@sharecancersupport.org</a><br /><br />Mei R. Fu, PhD, RN, ACNS-BC, FAAN<br />Associate Professor<br />College of Nursing<br />New York University</span>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-48520335287687039412014-09-10T12:06:00.001-04:002014-09-10T12:06:54.690-04:00Lymphedema Group Goes To Washington - WICU12 HD WSEE Erie, PA News, Sports, Weather, Events<a href="http://www.erietvnews.com/Clip/10566636/lymphedema-group-goes-to-washington#.VBB3ABaKBSc.blogger">Lymphedema Group Goes To Washington - WICU12 HD WSEE Erie, PA News, Sports, Weather, Events</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-49848127022589802622014-06-26T13:28:00.001-04:002014-06-26T13:28:11.312-04:00Brooke Anderson Breaks a Silence on Lymphedema<a href="http://lymphaticnetwork.org/news-events/brooke-anderson-breaks-a-silence#.U6xX-PUQjCE.blogger">Brooke Anderson Breaks a Silence</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-15488333344937483312014-06-17T06:33:00.001-04:002014-06-17T06:33:53.275-04:00StepUp-SpeakOut News Trends<a href="http://paper.li/StepupSpeakOut1/1400345143">StepUp-SpeakOut News Trends</a><br /><br />
<br /><br />
<span style="background-color: rgba(255, 255, 255, 0);">Our weekly newsletter on all things Lymphedema, Breast Cancer and Health trending in the news</span>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-53111742731393583692014-06-13T07:30:00.000-04:002014-06-13T07:30:19.605-04:00Massage and Cancer: Lymph Nodes Removed? Beware Increased Risk of Lymphedema. Spa Massages<a href="http://cincovidas.com/massage-and-cancer-lymph-nodes-removed-beware-increased-risk-of-lymphedema/">http://cincovidas.com/massage-and-cancer-lymph-nodes-removed-beware-increased-risk-of-lymphedema/</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-3179835477115125252014-06-04T10:14:00.003-04:002014-06-04T10:14:58.444-04:00Lasers and Night-Vision Technology Help Improve Imaging of Hidden Lymphatic SystemLasers and Night-Vision Technology Help Improve Imaging of Hidden Lymphatic System<div>
<br /></div>
<div>
<h2 style="border: 0px; margin: 0px; outline: 0px; padding: 0px 0px 0px 6px;">
<span style="font-size: small;"><span style="background-color: rgba(255, 255, 255, 0);">UTHealth researchers’ new device called "NIRFLI" may allow doctors to sooner detect and better manage cancer therapy and lymphedema</span></span></h2>
</div>
<div>
<div>
<br /></div>
<div>
<a href="http://www.marketwatch.com/story/lasers-and-night-vision-technology-help-improve-imaging-of-hidden-lymphatic-system-2014-06-03?reflink=MW_news_stmp.com">http://www.marketwatch.com/story/lasers-and-night-vision-technology-help-improve-imaging-of-hidden-lymphatic-system-2014-06-03?reflink=MW_news_stmp.com</a></div>
</div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-14140692359137463082014-05-29T10:56:00.001-04:002014-05-29T10:56:03.485-04:00NYU researchers pilot educational and behavioral program to reduce lymphedema risk <a href="http://www.sciencecodex.com/nyu_researchers_pilot_educational_and_behavioral_program_to_reduce_lymphedema_risk-134520#.U4dKWvgHh0E.blogger">NYU researchers pilot educational and behavioral program to reduce lymphedema risk | Science Codex</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-84371640454045992852014-05-27T11:15:00.000-04:002014-05-27T11:15:36.931-04:00Should Traditional Massage be used in the Treatment and Management of Lymphedema? Joe ZutherGeneral <a href="http://futurelmt.com/lmt-blog/manual-lymph-drainage/2008/03/03/should-traditional-massage-be-used-in-the-treatment-and-management-of-lymphedema/">Should Traditional Massage be used in the Treatment and Management of Lymphedema? </a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-53841662624669591492014-05-21T07:29:00.001-04:002014-05-21T07:29:24.130-04:00This is your brain on meditation: Brain processes more thoughts, feelings during meditation, study shows -- ScienceDaily<a href="http://www.sciencedaily.com/releases/2014/05/140515095545.htm#.U3yNT0DpZt1.blogger">This is your brain on meditation: Brain processes more thoughts, feelings during meditation, study shows -- ScienceDaily</a><br /><br />
<br /><br />
Interesting research findings on meditation.Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-36110447461775424012014-05-21T05:38:00.001-04:002014-05-21T05:38:54.347-04:00Full serving of protein at each meal needed for maximum muscle health -- ScienceDaily<a href="http://www.sciencedaily.com/releases/2014/05/140520133218.htm#.U3xzx_y-SaU.blogger">Full serving of protein at each meal needed for maximum muscle health -- ScienceDaily</a><br /><br />
<br /><br />
Be sure to include protein in your breakfast and lunch!Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-83785296646645491352014-05-20T16:19:00.001-04:002014-05-20T16:19:28.304-04:00Bacteria can linger on airplane surfaces for days -- ScienceDaily<a href="http://www.sciencedaily.com/releases/2014/05/140520100420.htm#.U3u4oxb3qTc.blogger">Bacteria can linger on airplane surfaces for days -- ScienceDaily</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-17274370384971846022014-05-17T15:39:00.001-04:002014-05-17T15:39:56.736-04:00Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer<h1 style="background-color: white; border: 0px; color: #11427c; font-family: Arial, Helvetica, sans-serif; font-size: 25px; line-height: 30px; margin: 4px 0px 7px; outline: 0px; padding: 0px 20px 0px 0px; vertical-align: baseline;">Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer</h1><div><span style="background-color: white; font-family: Arial, Helvetica, sans-serif; font-size: 13px; line-height: 18px;">Patients with early-stage breast cancer who underwent sentinel lymph node dissection experienced lymphedema with increasing incidence over time, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix.</span></div><div><span style="background-color: white; font-family: Arial, Helvetica, sans-serif; font-size: 13px; line-height: 18px;"><br /></span></div><div><span style="background-color: white; font-family: Arial, Helvetica, sans-serif; font-size: 13px; line-height: 18px;">See full article:</span></div><a href="http://www.ascopost.com/issues/may-15,-2014/lymphedema-lingers-long-after-sentinel-lymph-node-dissection-for-early-breast-cancer.aspx">http://www.ascopost.com/issues/may-15,-2014/lymphedema-lingers-long-after-sentinel-lymph-node-dissection-for-early-breast-cancer.aspx</a>Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-69991011453636355902014-04-23T15:10:00.000-04:002014-04-23T15:30:50.621-04:00Emory Law TI:GER team wins startup tourney, aims to produce lymphedema tool<div class="news-single-timedata" style="border: 0px; margin: 0px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">April 21, 2014 15:47 Age: 1 days</span></div>
<h2 style="border: 0px; font-weight: inherit; margin: 0px 0px 10px; outline: 0px; padding: 0px; vertical-align: top;">
<a href="https://blogger.googleusercontent.com/img/proxy/AVvXsEjQC88pfWWr5MxIak0b0AkAaKkJwtPQwLB5hA8Tzuc3pCRQyocUkfZIu5tT0ckC5o0Vrb8TnfQ44lGsiKJyqc_8y34ARX553kXqBAKThU0iAJtZJ1qDvh4yCb3fGfEUabdL9mSy7AcxvnAC0xSXBo1K9nGjEyGceAPmpFEsw1-FrYByZOhjDDE6Zk_cuRhO4DAX2UNMW1-_ciNLgg=" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><span style="font-size: small;"><span style="background-color: rgba(255, 255, 255, 0);"><a href="http://www.law.emory.edu/about-emory-law/news-article/article/emory-law-tiger-team-wins-startup-tourney-aims-to-produce-lymphedema-tool.html">Emory Law TI:GER team wins startup tourney, aims to produce lymphedema too</a></span></span></h2>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj9HBJ8L8H4XdF1L2v3MrEEHVHeZSoAvVuqPec9TsrVnhql4pyILwON5AJFvs7QYhHfJAjUGP_7kk3cA5wz-X4RNnRVQvJsa3I31fHh4UfF28xxv1PS1mA2R2Z6xtwAm47d549_lHQZDpI/s1600/emory.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj9HBJ8L8H4XdF1L2v3MrEEHVHeZSoAvVuqPec9TsrVnhql4pyILwON5AJFvs7QYhHfJAjUGP_7kk3cA5wz-X4RNnRVQvJsa3I31fHh4UfF28xxv1PS1mA2R2Z6xtwAm47d549_lHQZDpI/s1600/emory.jpg" /></a></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">A five-man team of Emory Law and Georgia Tech students recently took home sixth place at an international startup competition. They now hope to market their winning idea — a medical device to prevent a painful and disfiguring disease that affects nearly half of all breast cancer survivors.</span><br />
<span style="background-color: rgba(255, 255, 255, 0);"><br /></span>
<span style="background-color: white; color: #363636; font-family: arial, helvetica, verdana, sans-serif; font-size: 12px; line-height: 21px;">The LymphaTech team: Salim Vagh 14 (Tech), Robert Jones 14L, Nathan Frank 14 (Tech), Jeff Adams 14L, Mike Weiler 15 (Tech)</span><br />
<span style="background-color: rgba(255, 255, 255, 0);"><br /></span>
<span style="background-color: rgba(255, 255, 255, 0);">The </span><a href="http://www.law.emory.edu/about-emory-law/news-article/article/academics/academic-programs/tiger.html" style="border: 0px; font-style: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: top;">TI:GER</a><span style="background-color: rgba(255, 255, 255, 0);"> LymphaTech team focus is a diagnostic tool to prevent lymphedema, which causes an abnormal fluid buildup when lymph vessels or nodes are missing, damaged or removed. It would allow patients to regularly monitor themselves to detect swelling—critical because the condition is irreversible if not treated early.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">“The device works by optically measuring lymphatic pressure, like a blood pressure cuff for your lymphatic system,” said Emory Law student <b>Robert</b> <b>Jones</b> <b>14L</b>. “It’s a significant advancement over the current diagnostic gold standard, an ordinary tape measure, which is ineffective at catching the swelling until it becomes permanent.”</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">On April 12, the Emory Law/Tech team placed sixth at the Rice Business Plan Competition, which is billed as the world’s richest and largest such tourney for graduate students.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">“It’s the hardest [startup competition] in the country to get into,” said Margi Berbari, Tech’s TI:GER program director. “Not only were they accepted, they won sixth place, best presentation and the Women’s Health Award for a total of $38,000. They’re on a roll.”</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">In their pitch, LymphaTech sought $2 million in funding for FDA human clinical trials and a comparative effectiveness study for insurance reimbursement approval.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">“We’re no longer treating this like a class,” Jones said. “We’re focused on further laboratory research, prototype development, securing a license with Georgia Tech, and solidifying our FDA trials strategy,” Jones said. “We’re able to fund these initial steps using our competition winnings, and we will continue to seek additional funding.”</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">There are only six labs worldwide that perform this type of lymphatic research and none of the other labs have shown interest in commercialization, Jones said.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">“Also, we’ve faced hurdles in own path to market, and the knowledge and connections we’ve gained while overcoming those definitely give us an advantage going forward,” he said.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">The TI:GER team was chosen for one of 42 slots to present at the Rice competition from more than 500 applications. Teams present over three days, accelerating from a practice round and elevator pitch on Thursday, to semifinal, shark tank and final rounds on Saturday.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">The LymphaTech team is:<b> Jeff Adams 14L, Robert Jones 14L</b>, Mike Weiler, Nate Frank and Salim Vagh. Adams focuses on contract law and healthcare regulatory practices, and Jones covers patent and intellectual property issues. On the Tech side, Weiler is a biomedical engineering PhD student who developed the idea from his work at Tech’s Laboratory of Lymphatic Biology and Bioengineering; Frank and Vagh are MBA candidates. Team advisors are Dr. Amelia Zelnak, Assistant Professor Brandon Dixon and Robert McNally. Administrative Professor Anne Rector directs the TI:GER program at Emory Law.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">The next stop for the team is the <a href="http://www.mccombs.utexas.edu/Centers/Texas-Venture-Labs/Investment-Competition/Global-Competition" style="border: 0px; font-style: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: top;" target="_blank">2014 Global Venture Labs Investment Competition</a> held May 1-3, in Austin, Texas.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">In 14 years, The Rice Business Plan Competition has grown from nine teams competing for $10,000 in prizes in 2001 to 42 international teams angling for a purse of more than $1.3 million in cash and prizes.</span></div>
<div style="border: 0px; margin-bottom: 10px; outline: 0px; padding: 0px; vertical-align: top;">
<span style="background-color: rgba(255, 255, 255, 0);">“The competition is designed to give collegiate entrepreneurs a real-world experience to fine tune their business plans and elevator pitches to generate funding to successfully commercialize their product,” according to the competition site. A majority of the 250 volunteer judges are from the investment sector, and rank teams on which company they would most likely invest in.</span></div>
<!-- Blogger automated replacement: "https://images-blogger-opensocial.googleusercontent.com/gadgets/proxy?url=http%3A%2F%2Fwww.law.emory.edu%2Fabout-emory-law%2Fnews-article%2Farticle%2Ftypo3temp%2Fpics%2F4970330e47.jpg&container=blogger&gadget=a&rewriteMime=image%2F*" with "https://blogger.googleusercontent.com/img/proxy/AVvXsEjQC88pfWWr5MxIak0b0AkAaKkJwtPQwLB5hA8Tzuc3pCRQyocUkfZIu5tT0ckC5o0Vrb8TnfQ44lGsiKJyqc_8y34ARX553kXqBAKThU0iAJtZJ1qDvh4yCb3fGfEUabdL9mSy7AcxvnAC0xSXBo1K9nGjEyGceAPmpFEsw1-FrYByZOhjDDE6Zk_cuRhO4DAX2UNMW1-_ciNLgg=" -->Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0tag:blogger.com,1999:blog-1760688698583777296.post-62861651176345651182014-04-17T08:21:00.000-04:002014-04-17T08:21:10.697-04:00Interesting, give up our bras to help decrease breast cancer?<div class="userContentWrapper aboveUnitContent" data-ft="{"tn":"K"}" style="margin-bottom: 15px; margin-top: 15px;">
<div class="_wk mbm" style="margin-bottom: 10px;">
<span class="userContent" style="background-color: rgba(255, 255, 255, 0);"><a href="http://justjanuarysjargon.wordpress.com/2013/05/14/a-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation/">Interesting, give up our bras to help decrease breast cancer?</a></span></div>
</div>
<div class="_5rny">
<div class="_1xw clearfix" style="-webkit-box-shadow: rgba(0, 0, 0, 0.14902) 0px 1px 3px -1px; border: 0px; margin-bottom: 12px; zoom: 1;">
<a class="shareLink _1y0" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=MAQH_0jWkAQGykIeyj4nOqB_B58TWGQPF3_qfWIVV6EFBaA&enc=AZNvnuWWlIzFyZFCD_dCXa9CuecrIbH9yWqD6qAqrofnWnd8UKD_VjBqfo3_Tol1BwR1dWmmN565g0LUtl8f_e0q&s=1" rel="nofollow" style="cursor: pointer;" target="_blank"></a><br />
<div class="_1xy _1xx" style="background-color: rgba(255, 255, 255, 0); border: 0px; float: left; height: 116px; margin-right: 12px; min-width: 72px; position: relative; text-align: start; vertical-align: top; zoom: 1;">
<a class="shareLink _1y0" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=MAQH_0jWkAQGykIeyj4nOqB_B58TWGQPF3_qfWIVV6EFBaA&enc=AZNvnuWWlIzFyZFCD_dCXa9CuecrIbH9yWqD6qAqrofnWnd8UKD_VjBqfo3_Tol1BwR1dWmmN565g0LUtl8f_e0q&s=1" rel="nofollow" style="cursor: pointer;" target="_blank"><span style="color: black;"><img alt="" class="_42xb img" height="116" src="https://fbstatic-a.akamaihd.net/rsrc.php/v2/y4/r/-PAXP-deijE.gif" style="background-image: url(https://fbexternal-a.akamaihd.net/safe_image.php?d=AQBP52ANN58ZBgvq&w=116&h=116&url=http%3A%2F%2F1.gravatar.com%2Fblavatar%2F74e1e0f61d33210611c71cd59d5bdb92%3Fs%3D200&cfs=1); background-position: 50% 50%; background-repeat: no-repeat no-repeat; border: 0px; vertical-align: middle;" width="116" /></span></a></div>
<a class="shareLink _1y0" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=MAQH_0jWkAQGykIeyj4nOqB_B58TWGQPF3_qfWIVV6EFBaA&enc=AZNvnuWWlIzFyZFCD_dCXa9CuecrIbH9yWqD6qAqrofnWnd8UKD_VjBqfo3_Tol1BwR1dWmmN565g0LUtl8f_e0q&s=1" rel="nofollow" style="cursor: pointer;" target="_blank">
</a><br />
<div class="_1xx _1xz" style="-webkit-box-shadow: rgb(204, 204, 204) 0px 1px 6px -1px; border-color: rgb(233, 234, 237) rgb(218, 218, 218) rgb(204, 204, 204); border-style: solid; border-width: 1px; height: 90px; padding: 12px; vertical-align: top; zoom: 1;">
<div class="_2qo4" style="max-height: 98px;">
<a class="_2qo3" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=rAQGhD90oAQFtldWN-gnzCp8FCASO9pHln-ijUsEF4zPHtw&enc=AZOUOYCi7sEPBpG56t413ReDut7El8j5TvOVl27EftKHhxsqx39jm33KCsObi9RkmBvzwsdGXVmt4l0nrMxpGgXS&s=1" rel="nofollow" style="cursor: pointer; text-decoration: none;" target="_blank"></a><br />
<div class="_1x-" style="height: 58px; max-height: 98px; overflow: hidden;">
<div class="_4ysy" id="u_0_3a" style="background-color: rgba(255, 255, 255, 0); margin: 0px; padding: 0px;">
<a class="_2qo3" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=rAQGhD90oAQFtldWN-gnzCp8FCASO9pHln-ijUsEF4zPHtw&enc=AZOUOYCi7sEPBpG56t413ReDut7El8j5TvOVl27EftKHhxsqx39jm33KCsObi9RkmBvzwsdGXVmt4l0nrMxpGgXS&s=1" rel="nofollow" style="cursor: pointer; text-decoration: none;" target="_blank"><span style="color: black;"></span></a><br />
<div class="_1x_ fwb" dir="ltr" style="font-weight: bold;">
<a class="_2qo3" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=rAQGhD90oAQFtldWN-gnzCp8FCASO9pHln-ijUsEF4zPHtw&enc=AZOUOYCi7sEPBpG56t413ReDut7El8j5TvOVl27EftKHhxsqx39jm33KCsObi9RkmBvzwsdGXVmt4l0nrMxpGgXS&s=1" rel="nofollow" style="cursor: pointer; text-decoration: none;" target="_blank"><span style="color: black;">Why have we been conditioned to wear a tourniquet around our lymph system?</span></a></div>
<a class="_2qo3" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=rAQGhD90oAQFtldWN-gnzCp8FCASO9pHln-ijUsEF4zPHtw&enc=AZOUOYCi7sEPBpG56t413ReDut7El8j5TvOVl27EftKHhxsqx39jm33KCsObi9RkmBvzwsdGXVmt4l0nrMxpGgXS&s=1" rel="nofollow" style="cursor: pointer; text-decoration: none;" target="_blank"><span style="color: black;">
<div class="fsm fwn fcg">
justjanuarysjargon.wordpress.com</div>
</span></a></div>
</div>
<a class="_2qo3" href="http://l.facebook.com/l.php?u=http%3A%2F%2Fjustjanuarysjargon.wordpress.com%2F2013%2F05%2F14%2Fa-few-reasons-why-i-wont-be-following-in-angelina-jolies-footsteps-even-though-i-am-in-a-similar-situation%2F&h=rAQGhD90oAQFtldWN-gnzCp8FCASO9pHln-ijUsEF4zPHtw&enc=AZOUOYCi7sEPBpG56t413ReDut7El8j5TvOVl27EftKHhxsqx39jm33KCsObi9RkmBvzwsdGXVmt4l0nrMxpGgXS&s=1" rel="nofollow" style="cursor: pointer; text-decoration: none;" target="_blank">
</a></div>
</div>
</div>
</div>
Anonymoushttp://www.blogger.com/profile/05102162255875901128noreply@blogger.com0